Rodman & Renshaw initiates coverage of Vivus

Vivus, Inc. coverage was initiated by Rodman & Renshaw, LLC analyst Ilya Kravets with a market outperform rating and a $7 price target. The Mountain View, Calif., pharmaceutical company's product pipeline that includes four clinical stage product candidates, including Alista for the treatment of female sexual arousal disorder, Testosterone-MDTS to treat hypoactive sexual desire disorder, Evamist to alleviate symptoms associated with menopause and Avanafil, an inhibitor product candidate for the treatment of erectile dysfunction. Shares closed down $0.17, or 5.17%, at $3.12 on volume of 68,125 shares versus the three-month running average of 127,078 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.